Medlab granted approval for two cannabis trials

Company News

by Jessica Amir

Medlab Clinical Limited (ASX:MDC) has been granted approval for two different cannabis based human trials. It was granted approval by the Human Research Ethics Committee.

The medical research and development company says the patent pending medicines, NanaBis and NanaBidial, have two different applications and will be clinically tested at different locations.

The company NanaBis trial will be conducted at the Royal North Shore Hospital’s Northern Cancer Centre on advanced stage cancer patients with intractable pain.

Medlab says the trials mark a significant breakthrough for Australian medicine and are a massive advancement in global cannabis research

Both trials are expected to commence shortly.

Shares in Medlab Clinical Limited (ASX:MDC) are trading 0.63 per cent higher to 80 cents.
 

Jessica Amir

Finance News Network
Jessica presents the Market Outlook and company news. She joined FNN in January 2017. She has been in broadcast journalism for over five years. She has worked as a journalist with Sky News Business, ABC 1 and ABC24. She has also worked in regional Australia for Prime 7 and WIN News. She is also a qualified financial planner and a Masters of Applied Finance student.